Résumé
Les patientes présentant un cancer métastatique demeurent dans une situation incurable mais pour laquelle les progrès thérapeutiques ont permis d’améliorer considérablement à la fois la qualité de vie et le pronostic. Bénéfice acquis alors que les thérapeutiques les plus efficaces sont logiquement utilisées à la phase adjuvante pour guérir le maximum de patientes. Cette exposition en adjuvant exerce une pression de sélection importante qui voit récidiver des tumeurs résistantes, plus agressives et théoriquement de moins bon pronostic. Malgré cela, la maladie métastatique peut être chronicisée par nos thérapeutiques et le contrôle de la maladie métastatique ne cesse d’être amélioré [1]. P. Greenberg, en analysant des patientes traitées dans les années 1990 par des protocoles à base d’anthracycline, avait mis en évidence des survies prolongées au-delà de dix ans pour plus de 10 % des patientes présentant une réponse complète avec la première ligne de chimiothérapie [2]. Aujourd’hui, cette proportion est considérablement augmentée et il est parfaitement justifié de proposer aux patientes des lignes itératives de traitements avec espoir d’efficacité. Les armes à notre disposition pour contrôler cette maladie métastatique combinent les traitements hormonaux, les chimiothérapies et les nouvelles thérapeutiques ciblées.
Preview
Unable to display preview. Download preview PDF.
Références
Giordano SH, Buzdar AU, Smith TL et al. (2004) Is breast cancer survival improving? Cancer 100: 44–52
Greenberg PA, Hortobagyi GN, Smith TL et al. (1996) Long-term followup of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–2205
Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748–3757
Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606
Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767
Klijn JG, Beex LV, Mauriac L et al. (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92: 903–911
Klijn JG, Blamey RW, Boccardo F et al. (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343–353
Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460
Pivot X, Asmar L, Buzdar AU et al. (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82: 529–534
Pivot X, Asmar L, Hortobagyi GN (1999) The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol 15: 381–386
Paridaens R, Biganzoli L, Bruning P et al. (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724–733
Chan S, Friedrichs K, Noel D et al. (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354
Bontenbal M, Creemers GJ, Braun HJ et al. (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23: 7081–7088
Jassem J, Pienkowski T, Pluzanska A et al. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707–1715
Fumoleau P, Largillier R, Clippe C et al. (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536–542
O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823
Dufresne A, Pivot X, Tournigand C et al. (2008) Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107: 275–279
Pivot XB, Li RK, Thomas ES et al. (2009) Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptorhuman epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer 45: 2940–2946
Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274
Wardley AM, Pivot X, Morales-Vasquez F et al. (2010) Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer. J Clin Oncol 28: 976–983
von Minckwitz G, du Bois A, Schmidt M et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27: 1999–2006
Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743
Kaufman B, Mackey JR, Clemens MR et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537
Johnston S, Pippen J, Jr., Pivot X et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538–5546
Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676
Miller KD (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3(6): 421–422
Gray R, Bhattacharya S, Bowden C et al. (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27: 4966–4972
Marty M, Pivot X (2008) The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with antiangiogenic agents, focusing on bevacizumab. Eur J Cancer 44: 912–920
Chan A, Miles DW, Pivot X (2010) Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 21: 2305–2315
Barrios CH, Liu MC, Lee SC et al. (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121: 121–131
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag France
About this chapter
Cite this chapter
Villanueva, C., Bazan, F., Chaigneau, L., Cals, L., Sylvestre, V., Pivot, X. (2011). Traitements systémiques des cancers du sein métastatiques. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_13
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0021-9_13
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0020-2
Online ISBN: 978-2-8178-0021-9